Abiopharma

CERIBELL, INC. (CBLL)

Symbol	CBLL
Name	CERIBELL, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Electromedical & Electrotherapeutic Apparatus
Address	360 N. PASTORIA AVENUE, SUNNYVALE, California, 94085, United States
Telephone	+1 800 436-0826
Fax	—
Email	—
Website	https://www.ceribell.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001861107
Description	CeriBell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. We are initially focused on becoming the standard of care for the detection and management of seizures in the acute care setting. The Ceribell System has been adopted by more than 450 active accounts, ranging from top academic centers to small community hospitals, and has been used to care for over 100,000 patients. Additional info from NASDAQ: CeriBell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. We are initially focused on becoming the standard of care for the detection and management of seizures in the acute care setting. The Ceribell System has been adopted by more than 450 active accounts, ranging from top academic centers to small community hospitals, and has been used to care for over 100,000 patients.

2026-08-17 22:27

Chao Xingjuan 🟡 adjusted position in 0 shares (2 derivative) of Ceribell, Inc. (CBLL) at $3.65 Transaction Date: Aug 13, 2026 | Filing ID: 354402

2026-08-14 18:37

Taylor Joseph Michael 🔴 sold 13.1K shares of Ceribell, Inc. (CBLL) at $23.40 Transaction Date: Aug 13, 2026 | Filing ID: 351878

2026-08-14 17:50

New Form SCHEDULE 13G/A - Ceribell, Inc. Filed: 2026-08-14 AccNo: 0001999371-26-018019 Size: 13 KB

2026-08-13 14:29

📋 Taylor Joseph Michael (Director) plans to sell 13K shares of Ceribell, Inc. (at $22.91 each, total $300K) Filed: Aug 13, 2026 | ID: 000003

2026-08-10 20:27

(30% Negative) CERIBELL, INC. (CBLL) Reports Q3 2026 Financial Results

2026-08-10 20:05

Ceribell Reports Second Quarter 2026 Financial Results

2026-08-10 11:00

Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

2026-08-03 11:00

Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

2026-07-30 23:43

West Thomas A. 🟢 acquired 16.0K shares of Ceribell, Inc. (CBLL) Transaction Date: Jul 28, 2026 | Filing ID: 326487

2026-07-30 23:39

O'KEEFE SHARON 🟢 acquired 16.0K shares of Ceribell, Inc. (CBLL) Transaction Date: Jul 28, 2026 | Filing ID: 326486

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07485244	EEG Abnormalities in Adult ICU Patients With High Risk of Delirium	—	Delirium in the Intensive Care Unit	Recruiting	2026-04-16	2027-09-30	ClinicalTrials.gov
NCT07449416	Ceribell Delirium Monitor Outcomes Pilot Study	Na	Delirium in the Intensive Care Unit	Recruiting	2026-03-15	2026-12-01	ClinicalTrials.gov

Total clinical trials: 2

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Ceribell Delirium Monitoring System	Other	Approved	Delirium in the Intensive Care Unit	RECRUITING	NCT07449416
Ceribell Delirium Monitoring System	Other	Approved	Delirium in the Intensive Care Unit	NOT_YET_RECRUITING	NCT07449416
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244
Ceribell EEG System	Other	Preclinical	Delirium in the Intensive Care Unit	RECRUITING	NCT07485244

Total products: 11